Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Monday, June 27, 2011

(2nd article) FDA Safety Alerts for Human Medical Products > Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Epoetin alfa (marketed as Epogen and Procrit) and darbepoetin alfa (marketed as Aranesp)

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.